Radioimmunotherapy

Radio immunotherapy utilizes an antibody labeled with a radionuclide to deliver cytotoxic radiation to a target cell. In cancer therapy, an antibody with specificity for a tumor-associated antigen is used to deliver a lethal dose of radiation to the tumor cells. The ability for the antibody to specifically bind to a tumor-associated antigen increases the dose delivered to the tumor cells while decreasing the dose to normal tissues. By its nature, RIT requires a tumor cell to express an antigen that is unique to the neoplasm or is not accessible in normal cells. (From the Wikpedia article Radioimmunotherapy.)

Download PDF

Recent Publications on Radioimmunotherapy:
Tomoregulin internalization confers selective cytotoxicity of immunotoxins on prostate cancer cells. We have recently identified and validated the prostate cancer antigen...	18th July, 2008	Department of Cancer Research, Berlex Biosciences, Richmond, CA, USA.	Transl Oncol. 2008 Jul;1(2):102-9.
Perspectives of molecular imaging and radioimmunotherapy in lymphoma. Successful treatment of Hodgkin lymphomas and non-Hodgkin lymphomas...	16th July, 2008	Department of Radiology, Division of Nuclear Medicine, Stanford University	Radiol Clin North Am. 2008 Mar;46(2):243-52. DOI Direct Link
Pulmonary marginal zone lymphoma: a single centre experience and review of the SEER database. Pulmonary marginal zone lymphoma is a rare disease arising from...	8th July, 2008	Department of Medicine, Division of Hematology-Oncology, Sylvester	Leuk Lymphoma. 2008 Jul;49(7):1311-20. DOI Direct Link
How have outcomes for patients with follicular lymphoma changed with the addition of monoclonal antibodies? The outcome for patients with follicular lymphoma (FL) has substantially...	8th July, 2008	School of Cancer and Imaging Sciences, University of Manchester,	Leuk Lymphoma. 2008 Jul;49(7):1263-73. DOI Direct Link
Improved therapeutic results by pretargeted radioimmunotherapy of non-Hodgkin's lymphoma with a new recombinant, trivalent, anti-CD20, bispecific antibody. We examined whether a pretargeting method using a new recombinant...	3rd July, 2008	Garden State Cancer Center, Center for Molecular Medicine and Immunology,	Cancer Res. 2008 Jul 1;68(13):5282-90. DOI Direct Link
→View more research publications.

BioNews Results for Radioimmunotherapy:
Radioimmunotherapy Targets Metastatic Melanoma Lesions in Phase I Trial	Medscape:  Jul 2 2008 7:10PM Matching: radioimmunotherapy
Radioimmunotherapy Targets Metastatic Melanoma Lesions in Phase I Trial	Abstracts in Hematology and Oncology:  Jul 2 2008 5:43PM Matching: radioimmunotherapy
Radioimmunotherapy targets metastatic melanoma lesions in phase I trial	Aunt Minnie:  Jul 2 2008 9:16AM Matching: radioimmunotherapy
Radioimmunotherapy targets metastatic melanoma lesions in phase I trial	Clinical Lab Products:  Jul 2 2008 1:22AM Matching: radioimmunotherapy
Radiolabeled and Native Antibodies and the Prospect of Cure of Follicular Lymphoma Franz Buchegger, Oliver W.	The Oncologist:  Jun 28 2008 12:18PM Matching: radioimmunotherapy
Promote your company here: BioNewsCast - Press Release Distribution	→View more news.

Radioimmunotherapy Clinical Trials:
BEAM+131I-Anti-B1 & Autologous Hematopoietic Stem Cell Transplant for Recurrent Non-Hodgkin's Lymphoma	Lymphoma Intervention: Radiation: 131Iodine-Anti-B1 Radioimmunotherapy

Radioimmunotherapy Patents:
US Patent No.	Title
7288534	Sphingomyelin enhancement of tumor therapy
7323300	Methods for cancer prognosis and diagnosis
7323553	Non-affinity purification of proteins
7329402	Methods of imaging and treatment
7338659	Reducing immunogenicities of immunoglobulins by framework-patching
→View more patents.

Companies working in the area of Radioimmunotherapy from Bioportfolio's Biocorporate database :
Company Name
Center of Molecular Immunology The Center of Molecular Immunology (CIM) is a Cuban Biotechnological Institution devoted to basic research, product development and production of mammalian cell culture products such as monoclonal... www.cim.sld.cu/        View full profile

BioPortfolio Ltd. offers e-mail and postal lists for Radioimmunotherapy scientists - we have details of around 267 individuals working on Radioimmunotherapy .

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.  See User Agreement

Send comments and feedback to:
Peter Barfoot Managing Director, BioPortfolio Ltd.
UK Tel: (+44) 1300 321501
USA Voicemail and Fax: (+1) 415 680 2472

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Wessex Barn, Dorchester Road, Frampton, Dorset, DT2 9NB, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2008 - BioPortfolio Limited.